Adial Pharmaceuticals Stock (NASDAQ:ADIL)
Previous Close
$0.36
52W Range
$0.22 - $1.30
50D Avg
$0.37
200D Avg
$0.57
Market Cap
$8.24M
Avg Vol (3M)
$829.06K
Beta
1.36
Div Yield
-
ADIL Company Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.